ArticleHuman immunology2026
Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIV.
Article in Human immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Cryptococcus neoformans is an opportunistic fungal infection and a leading cause of HIV-associated meningitis, contributing significantly to AIDS-related mortality, especially in Africa. Despite advancements in treatment, case fatality rates remain high, emphasizing the need for a better understanding of host immune responses. This study investigated the association between variation in the human leukocyte antigen (HLA) genes and the risk of cryptococcal disease in Ugandan individuals with HIV. We first described the allele prevalence in a prospectively enrolled Ugandan population using next-generation sequencing at a four-field resolution for classic HLA class I and II genes. We then conducted a case-control analysis involving 137 participants categorized as: 1) disseminated cryptococcosis but without meningitis, 2) cryptococcal meningitis, and 3) controls with similar degree of HIV disease but without cryptococcal infection. Across 66 unique alleles that met criteria for analysis, we found no significant associations between HLA variation and altered risk of disseminated cryptococcosis or cryptococcal meningitis after adjusting for multiple comparisons. However, before multiple comparisons correction, HLA-DPB1*04:01 demonstrated lower odds ratios for both disseminated disease and cryptococcal meningitis. Using public online databases, we analyzed predicted Cryptococcus peptide binding to HLA-DPB1*04:01 with predicted interferon-gamma responses and identified 121 viable peptides-leading us to hypothesize a role for the leading epitopes. This research underscores the need to further investigate the importance of the HLA system for host-pathogen interactions in HIV-associated cryptococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.